

## Special Issue

# Recent Advances in Orthopaedic Oncology

### Message from the Guest Editor

Bone and soft tissue sarcomas are infrequent and heterogenous tumours that account for 1% of all cancers. Distant metastasis is relatively common in high-grade tumours, and many basic studies focus on developing new systemic therapies for improving survival. Clinical research focuses on oncologic and functional outcomes after local and systemic treatment of tumours. Orthopaedic oncology also includes benign tumours. Some benign tumours such as giant cell tumours, solitary bone tumours, and desmoid tumours are often problematic and should be discussed. We are pleased to invite you to submit your work to this Special Issue on "Recent Advances in Orthopaedic Oncology". This Special issue aims to clinically investigate new diagnostic and therapeutic techniques. We also investigate the possible applications for future treatment in basic studies. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: bone sarcoma, soft tissue sarcoma, and benign bone and soft tissue tumours.

### Guest Editor

Dr. Tomoki Nakamura

Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu 514-8570, Japan

### Deadline for manuscript submissions

closed (31 August 2022)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/98571](https://mdpi.com/si/98571)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)